All forward-looking statements this news release this press release.

Under the Private Securities Litigation Reform Act of 1995: This press release contains certain forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. These statements are based on current expectations Aida Pharmaceuticals ‘ s management and are subject to risks and uncertainties and changes in circumstances. All forward-looking statements this news release this press release, on information Aida Pharmaceuticals , is based on the date of the press release, and it undertakes no obligation to update or alter its forward-looking statements, whether. As a result of new information, future events or otherwise These forward-looking statements may relate, contained among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, supply and demand, and other expectations, intentions and plans contained in this press release Further information on not historical facts.

Anti – CTLA-4 monoclonal antibody, tumor growth in the case of over-expressing certain types of cancer, tumors self proteins inhibit substantially hiding the tumor from the immune system. Aida Pharmaceuticals is in the developmental stages of the anti-CTLA-4 monoclonal antibodies, the inhibition of T – cells so that they become identify the overexpressed proteins and, in turn, of course, attack the cancer cells without can relieve healthy tissue.

Harold Sox, first editorial of the Annals of Internal Medicine that the editors the drug trial registry concept that ICMJE to place first, which is amplified in a joint editorial of September 2004. Our first editorial a wake up call for researchers, trial authors and sponsors of this editorial reaffirms our intent and tells the researchers what they need to do to meet our requirements for editorial review and subsequent publication, ‘said Sox.

Anti – CD86 monoclonal antibody to immunity diseases certain immunity diseases to activate T – cells , thereby unnecessarily treating attacking healthy tissue.These results are are written in a new and comprehensive overview and examines researches for Greystone Associates. The survey is the conclusion that on assume take full advantage of these developing dynamic, active transdermal participant need development with a series of economical and the market forces influenced the way in pharmaceutical companies deal and promote their products. Success will encourage this trade people willing patient centered design features and drug-device combining engineering paradigms of incorporate in its product development programs.

ATACAND on failure was the first ARBs order for the reduction for reducing either cardiovascular mortality and admissions for heart failure.. Atacand in first ARB authorization for the reduction is get momentum in CV cause mortality and hospitalizations due cardiac insufficiency – Astra Zeneca today announced that in that the U.S. Food and Drug administrative has approved its angiotensin receptor blocker ATACAND reduce tablets for treating to the heart failure (NYHA class II-IV and ejection fraction? the risk death from cardiovascular causes and hospital stay.